Saturday, January 12, 2013

SCATTERED NEWS

1. Adding Velcade may increase remission rates in AML.
This was suggested in a study at Massachusetts general Hospital.
2. CD25 was a new prognosis Biomarker in Adult B-ALL.
3. Ibrutinib in combination with Rituxan is effective in CLL
420 mg PO daily with weekly 375mg/m2 of Rituxan for 4 weeks
Rituxan was then continued monthly for 6 months
RR of 83% noted.
4. Preliminary suggestions that patients taking Statins may have a reduced risk of Hepatoma.
5 Pazopanib may be no inferior to Sutent as first line therapy in Metastatic renal cell cancer.
6. Axinitib failed to meet primary end point in Metastatic Renal cell cancer.

No comments: